Future Perspectives and Unmet Needs in Multiple Myeloma
The expert panel concludes their discussion by examining the unmet needs and future for the treatment landscape in multiple myeloma.
EP: 1.Determining Candidates for Transplant in Newly Diagnosed Multiple Myeloma
EP: 2.Quad Therapy and Risk Stratification in Multiple Myeloma
EP: 3.CAR T-cell Therapy Remains Preferred Options for Relapsed/Refractory Multiple Myeloma
EP: 4.Consolidation and Maintenance Therapy Considerations in Multiple Myeloma
EP: 5.Multiple Myeloma: Treatment Considerations and Role of MRD
EP: 6.Treatment Decision-Making and Assessing Frailty in Multiple Myeloma
EP: 7.Later-Line Therapy in Multiple Myeloma
EP: 8.Emerging Research in CAR T-Cell Therapy in R/R Multiple Myeloma
EP: 9.Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
EP: 10.Bispecific Antibody Selection in Multiple Myeloma
Now Viewing
EP: 11.Future Perspectives and Unmet Needs in Multiple Myeloma
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
